Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs

Journal of Immunology

Volumn 181, Issue 5, 2008, Pages 3183-3192

  Brezski, Randall J ^a   Luongo, Jennifer L ^a   Petrone, Diane ^a   Ryan, Mary H ^a   Zhong, Degang ^a   Tam, Susan H ^a   Schmidt, Albert P ^a   Kruszynski, Marian ^a   Whitaker, Brian P ^a   Knight, David M ^a   Jordan, Robert E ^a  

^a CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; AUTOANTIBODY; COMPLEMENT; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G1 HINGE AUTOANTIBODY; IMMUNOGLOBULIN G3; PROTEINASE; UNCLASSIFIED DRUG; AUTOANTIGEN; PEPTIDE HYDROLASE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CELL ASSAY; CELL FUNCTION; CONTROLLED STUDY; CYTOLYSIS; EFFECTOR CELL; HINGE REGION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; SEQUENCE ANALYSIS; ANTIBODY COMBINING SITE; ANTIGEN ANTIBODY COMPLEX; IMMUNOLOGY; METABOLISM;

ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; AUTOANTIGENS; BINDING SITES, ANTIBODY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; PEPTIDE HYDROLASES;

EID: 51549095449     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.5.3183     Document Type: Article

References (59)

1. Ryan, M. H., D. Petrone, J. F. Nemeth, E. Barnathan, L. Bjorck, and R. E. Jordan. 2008. Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid. Mol. Immunol. 45: 1837-1846.
2. Von Pawel-Rammingen, U., B. P. Johansson, and L. Bjorck. 2002. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J. 21: 1607-1615. (Pubitemid 34614617)
3. Fick, R. B., Jr., R. S. Baltimore, S. U. Squier, and H. Y. Reynolds. 1985. IgG proteolytic activity of Pseudomonas aeruginosa in cystic fibrosis. J. Infect. Dis. 151: 589-598. (Pubitemid 15102153)
4. Gearing, A. J., S. J. Thorpe, K. Miller, M. Mangan, P. G. Varley, T. Dudgeon, G. Ward, C. Turner, and R. Thorpe. 2002. Selective cleavage of human IgG by matrix metalloproteinases, matrilysin and stromelysin. Immunol. Lett. 81: 41-48. (Pubitemid 34159039)
5. LeMosy, E. K. 2004. IgA1-Specific Serine Endopeptidase. Elsevier Academic Press, San Diego.
6. Van Kempen, L. C., K. E. de Visser, and L. M. Coussens. 2006. Inflammation, proteases and cancer. Eur. J. Cancer 42: 728-734.
7. Nelson, A. R., B. Fingleton, M. L. Rothenberg, and L. M. Matrisian. 2000. Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. 18: 1135-1149. (Pubitemid 30123793)
8. Lannergard, J., and B. Guss. 2006. IdeE, an IgG-endopeptidase of Streptococcus equi ssp. equi. FEMS Microbiol. Lett. 262: 230-235. (Pubitemid 44272800)
9. Wenig, K., L. Chatwell, U. von Pawel-Rammingen, L. Bjorck, R. Huber, and P. Sondermann. 2004. Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG. Proc. Natl. Acad. Sci. USA 101: 17371-17376. (Pubitemid 39657411)
10. Yamaguchi, Y., H. Kim, K. Kato, K. Masuda, I. Shimada, and Y. Arata. 1995. Proteolytic fragmentation with high specificity of mouse immunoglobulin G: mapping of proteolytic cleavage sites in the hinge region. J. Immunol. Methods 181: 259-267.
11. Edelman, G. M., B. A. Cunningham, W. E. Gall, P. D. Gottlieb, U. Rutishauser, and M. J. Waxdal. 1969. The covalent structure of an entire γG immunoglobulin molecule. Proc. Natl. Acad. Sci. USA 63: 78-85.
12. Vincents, B., U. von Pawel-Rammingen, L. Björck, and M. Abrahamson. 2004. Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding. Biochemistry 43: 15540-15549. (Pubitemid 39647479)
13. Plaut, A. G. 1983. The IgA1 proteases of pathogenic bacteria. Annu. Rev. Microbiol. 37: 603-622.
14. Travis, J., and J. Potempa. 2000. Bacterial proteinases as targets for the development of second-generation antibiotics. Biochim. Biophys. Acta 1477: 35-50. (Pubitemid 30119890)
15. Coussens, L. M., and Z. Werb. 2002. Inflammation and cancer. Nature 420: 860-867.
16. Dollery, C. M., C. A. Owen, G. K. Sukhova, A. Krettek, S. D. Shapiro, and P. Libby. 2003. Neutrophil elastase in human arthrosclerotic plaques: production by macrophages. Circulation 107: 2829-2836.
17. Hartley, S. B., J. Crosbie, R. Brink, A. B. Kantor, A. Basten, and C. C. Goodnow. 1991. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature 353: 765-769.
18. Radic, M. Z., J. Erikson, S. Litwin, and M. Weigert. 1993. B lymphocytes may escape tolerance by revising their antigen receptors. J. Exp. Med. 177: 1165-1173.
19. Norvell, A., L. Mandik, and J. G. Monroe. 1995. Engagement of the antigen-receptor on immature murine B lymphocytes results in death by apoptosis. J. Immunol. 154: 4404-4413.
20. Wardemann, H., S. Yurasov, A. Schaefer, J. W. Young, E. Meffre, and M. C. Nussenzweig. 2003. Predominant autoantibody production by early human B cell precursors. Science 301: 1374-1377. (Pubitemid 37075812)
21. Tiller, T., M. Tsuiji, S. Yurasov, K. Velinzon, M. C. Nussenzweig, and H. Wardemann. 2007. Autoreactivity in human IgG memory B cells. Immunity 26: 205-213. (Pubitemid 46329436)
22. Artandi, S. E., K. L. Calame, S. L. Morrison, and V. R. Bonagura. 1992. Monoclonal IgM rheumatoid factors bind IgG at a discontinuous epitope comprised of amino acid loops from heavy-chain constant-region domains 2 and 3. Proc. Natl. Acad. Sci. USA 89: 94-98.
23. Knight, D. M., C. Wagner, R. Jordan, M. F. McAleer, R. DeRita, D. N. Fass, B. S. Coller, H. F. Weisman, and J. Ghrayeb. 1995. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol. Immunol. 32: 1271-1281.
24. 2 portion of IgG. Clin. Exp. Immunol. 42: 378-386.
25. Persselin, J. E., and R. H. Stevens. 1985. Anti-Fab antibodies in humans: predominance of minor immunoglobulin G subclasses in rheumatoid arthritis. J. Clin. Invest. 76: 723-730.
26. 2 antibody recognizes a conformational IgG1 hinge epitope. J. Immunol. 154: 6446-6452.
27. Persselin, J. E., and R. H. Stevens. 1985. Anti-Fab antibodies in humans: predominance of minor immunoglobulin G subclasses in rheumatoid arthritis. J. Clin. Invest. 76: 723-730.
28. Terness, P., D. Navolan, C. Dufter, M. Welschof, and G. Opelz. 2002. Immunosuppressive anti-immunoglobulin autoantibodies: specificity, gene structure and function in health and disease. Cell. Mol. Biol. 48: 271-278.
29. 2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty. Platelets 13: 465-477.
30. 2 from the circulation. Eur. J. Immunol. 25: 3128-3133.
31. Goetz, H., M. Kuschel, T. Wulff, C. Sauber, C. Miller, S. Fisher, and C. Woodward. 2004. Comparison of selected analytical techniques for protein sizing, quantitation and molecular weight determination. J. Biochem. Biophys. Methods 60: 281-293. (Pubitemid 39179383)
32. Kruszynski, M., P. Tsui, N. Stowell, J. Luo, J. F. Nemeth, A. M. Das, R. Sweet, and G. A. Heavner. 2006. Synthetic, site-specific biotinylated analogs of human MCP-1. J. Pept. Sci. 12: 354-360. (Pubitemid 43676806)
33. Scallon, B. J., S. H. Tam, S. G. McCarthy, A. N. Cai, and T. S. Raju. 2007. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol. Immunol. 44: 1524-1534.
34. 2γ autoantibody occurring in healthy individuals and kidney graft recipients recognizes an IgG1 hinge region epitope. J. Immunol. 157: 4251-4257.
35. Birdsall, H. H., and R. D. Rossen. 1983. Characterization of anti-Fab′ antibodies in human sera: identification of soluble immune complexes that contain hidden anti-KLH and blocking anti-immunoglobulins following immunization with keyhole limpet haemocyanin. Clin. Exp. Immunol. 53: 497-504.
36. 2 antibody with DNA and other nuclear antigens. Arthritis Rheum. 40: 109-123.
37. Hjortoe, G. M., L. C. Petersen, T. Albrektsen, B. B. Sorensen, P. L. Norby, S. K. Mandal, U. R. Pendurthi, and L. V. Rao. 2004. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 103: 3029-3037.
38. 2) system. J. Rheumatol. 22: 1075-1085.
39. 2 and autoantibody production in patients with cold agglutination. Blood 85: 548-551.
40. Susal, C., H. H. Oberg, V. Daniel, C. Dorr, P. Terness, A. Huth-Kuhne, R. Zimmermann, and G. Opelz. 1994. Isotypes and IgG subclasses of anti-Fab antibodies in human immunodeficiency virus-infected hemophilia patients. Vox Sang. 66: 37-45. (Pubitemid 24017155)
41. Baici, A., M. Knopfel, K. Fehr, F. Skvaril, and A. Boni. 1980. Kinetics of the different susceptibilities of the four human immunoglobulin G subclasses to proteolysis by human lysosomal elastase. Scand. J. Immunol. 12: 41-50. (Pubitemid 10071938)
42. Aster, R. H. 2005. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 127: 53S-59S.
43. Wagner, C. L., A. Schantz, E. Barnathan, A. Olson, M. A. Mascelli, J. Ford, L. Damaraju, T. Schaible, R. N. Maini, and J. E. Tcheng. 2003. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev. Biol. 112: 37-53.
44. Nimmerjahn, F., and J. V. Ravetch. 2008. Fcγ receptors as regulators of immune responses. Nat. Rev. Immunol. 8: 34-47.
45. Bruggemann, M., G. T. Williams, C. I. Bindon, M. R. Clark, M. R. Walker, R. Jefferis, H. Waldmann, and M. S. Neuberger. 1987. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 166: 1351-1361. (Pubitemid 18051427)
46. Salfeld, J. G. 2007. Isotype selection in antibody engineering. Nat. Biotechnol. 25: 1369-1372.
47. Jefferis, R. 2007. Antibody therapeutics: isotype and glycoform selection. Expert Opin. Biol. Ther. 7: 1401-1413. (Pubitemid 47475656)
48. Armour, K. L., M. R. Clark, A. G. Hadley, and L. M. Williamson. 1999. Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities. Eur. J. Immunol. 29: 2613-2624.
49. Armour, K. L., J. G. van de Winkel, L. M. Williamson, and M. R. Clark. 2003. Differential binding to human FcγRIIa and FcγRIIb receptors by human IgG wildtype and mutant antibodies. Mol. Immunol. 40: 585-593.
50. Lazar, G. A., W. Dang, S. Karki, O. Vafa, J. S. Peng, L. Hyun, C. Chan, H. S. Chung, A. Eivazi, S. C. Yoder, et al. 2006. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA 103: 4005-4010.
51. Canfield, S. M., and S. L. Morrison. 1991. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J. Exp. Med. 173: 1483-1491.
52. Morgan, A., N. D. Jones, A. M. Nesbitt, L. Chaplin, M. W. Bodmer, and J. S. Emtage. 1995. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc γ RI and Fc γ RIII binding. Immunology 86: 319-324.
53. Clark, M. R. 1997. IgG effector mechanisms. Chem. Immunol. 65: 88-110.
54. 2 autoantibodies: study of their interaction with IgG hinge region epitopes. Hum. Immunol. 60: 282-290.
55. 2 autoantibody. Proc. Natl. Acad. Sci. USA 94: 1902-1907.
56. Scallon, B., A. Cai, N. Solowski, A. Rosenberg, X. Y. Song, D. Shealy, and C. Wagner. 2002. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther. 301: 418-426. (Pubitemid 34429950)
57. Fogler, W. E., M. R. Klinger, K. G. Abraham, H. G. Gottlinger, G. Riethmuller, and P. E. Daddona. 1988. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen. Cancer Res. 48: 6303-6308.
58. Preithner, S., S. Elm, S. Lippold, M. Locher, A. Wolf, A. J. da Silva, P. A. Baeuerle, and N. S. Prang. 2006. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol. Immunol. 43: 1183-1193. (Pubitemid 43063171)
59. 2-containing immune complexes together with anti-hinge natural antibodies stimulate complement amplification in vitro and in vivo. Mol. Immunol. 45: 2951-2961.